Hamilton, Bermuda, April 24, 2024 (GLOBE NEWSWIRE) — Detailed results from randomized controlled Bentrio® trial in seasonal allergic rhinitis published […]
CINCINNATI, April 24, 2024 (GLOBE NEWSWIRE) — Workhorse Group Inc. (Nasdaq: WKHS) (“Workhorse” or “the Company”), an American technology company […]
MIAMI, April 24, 2024 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company […]
FORT WORTH, Texas, April 24, 2024 (GLOBE NEWSWIRE) — HighPeak Energy, Inc. (NASDAQ: HPK) (“HighPeak Energy”), today announced that it […]
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) — Grab Holdings Limited (NASDAQ: GRAB, the “Company” or “Grab”), plans to announce […]
The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with […]
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary […]
MIGDAL HAEMEK, Israel – April 24, 2024 – Tower Semiconductor (NASDAQ/ TASE: TSEM), the leading foundry of high-value analog semiconductor […]
HONG KONG, April 24, 2024 (GLOBE NEWSWIRE) — Futu Holdings Limited (“Futu” or the “Company”) (Nasdaq: FUTU), a leading tech-driven online […]
Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary […]
